Huaier Inhibits Gastric Cancer Growth and Hepatic Metastasis by Reducing Syntenin Expression and STAT3 Phosphorylation.
Yunfu ShiLi YuanJingli XuHandong XuLijing WangLing HuangZhiyuan XuXiang-Dong ChengPublished in: Journal of oncology (2022)
Gastric cancer (GC) is a common malignant tumor worldwide and poses a serious threat to human health. As a traditional Chinese medicine, Huaier ( Trametes robiniophila Murr.) has been used in the clinical treatment of GC. However, the mechanism underlying the anticancer effect of Huaier remains poorly understood. In this study, we used in vivo imaging technology to determine the anticancer effect of the Huaier n-butanol extract (HBE) on orthotopic and hepatic metastasis of GC mouse models. We found that HBE suppressed tumor growth and metastasis without causing apparent host toxicity. Proteomic analysis of GC cells before and after HBE intervention revealed syntenin to be one of the most significantly downregulated proteins after HBE intervention. We further demonstrated that HBE suppressed the growth and metastasis of GC by reducing the expression of syntenin and the phosphorylation of STAT3 at Y705 and reversing the epithelial-mesenchymal transition (EMT). In addition, we confirmed that syntenin was highly expressed in GC tissue and correlated with metastasis and poor prognosis. In conclusion, our results suggest that Huaier, a clinically used anticancer drug, may inhibit the growth and liver metastasis of GC by inhibiting the syntenin/STAT3 signaling pathway and reversing EMT.
Keyphrases
- poor prognosis
- epithelial mesenchymal transition
- signaling pathway
- gas chromatography
- long non coding rna
- human health
- randomized controlled trial
- induced apoptosis
- risk assessment
- cell proliferation
- oxidative stress
- high resolution
- mouse model
- transforming growth factor
- climate change
- computed tomography
- mass spectrometry
- magnetic resonance imaging
- binding protein
- endoplasmic reticulum stress
- contrast enhanced
- smoking cessation